Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 301-307

  Boyd, Mark ^a,b   Mootsikapun, Piroon ^c   Burger, David ^d   Chuenyam, Theshinee ^a   Ubolyam, Sasiwimol ^a   Mahanontharit, Apicha ^a   Sangkote, Jongkol ^a   Bunyaprawit, Parichart ^c   Horsakulchai, Manasinee ^c   Lange, Joep ^e   Cooper, David ^b   Phanuphak, Praphan ^a,f   Ruxrungtham, Kiat ^a,f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Srinagarind hospital   (Thailand)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; INDINAVIR; RITONAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; FEMALE; HELPER CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; OPEN STUDY; PRIORITY JOURNAL; THAILAND; VIRUS LOAD; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; HOSPITAL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HOSPITALS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE; THAILAND;

EID: 22844448412     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM & Sun E. Pnarmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrobial Agents & Chemotherapy 1998; 42:2784-2791.
2. Heeswijk van RPG, Veldkamp AI, Hoetelmans RMW, Mulder JW, Schreij G, Hsu A, Lange JMA, Beijnen JH & Meenhorst PL. The steady-state pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13:F95-F99.
3. Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JT, Reiss P & Lange JM. A retrospective, cohort-based survey of patients using twice daily indinavir + ritonavir combinations: pharmacokinetics, safety and efficacy. Journal of Acquired Immune Deficiency Syndromes 2001; 26:218-224.
4. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR & Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrobial Agents & Chemotherapy 2001; 45:2710-2715.
5. Aarnoutse RE, Wasmuth JC, Fatkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM & Rockstroh JK. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antiviral Therapy 2003; 8:309-314.
6. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fatkenheuer G, d'Arminio-Monforte A, Casiro A, Reiss P, Burger DM, Stek M & Gatell JM. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17:831-840.
7. Boyd M, Duncombe C, Ruxrungtham K, Khongphattanayothin M, Hassink E, Srasuebkol P, Sangkote J, Reiss P, Stek M, Lange JMA, Cooper DA & Phanupak P. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76 week follow-up. 9th Conference on Retroviruses & Opportunistic Infections. 24-28 February 2002, Seattle, WA, USA. Abstract 422-W.
8. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z & Lundgren JD. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCminl Trial. Journal of Infectious Diseases 2003; 188:635-642.
9. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P & Reiss P. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy 2003; 51:1231-1238.
10. Wasmuth JC, la Porte CJ, Schneider K, Burger DM & Rockstroh JK. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antiviral Therapy 2004; 9:213-220.
11. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, Bricaire F, Duvivier C, Calvez V, Peytavin G & Katlama C. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
12. Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G & Katlama C. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antiviral Therapy 2003; 8:603-609.
13. Droste JAH, Verweij-van Wissen CPWGM & Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Therapeutic Drug Monitoring 2003; 25:393-399.
14. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, 4th edn 1991; pp. 14-23. Edited by M Gibaldi. Philadelphia: Lea & Febiger.
15. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2003. www.aidsinfo.nih.gov/guidelines/adult
16. Optimising TDM in HIV Clinical Care. A Practical Guide to Performing Therapeutic Drug Monitoring (TDM) for Antiretroviral Agents. http://www.HIVpharmacology.com. Last accessed 24 May 2004.
17. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR & Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16:551-560.
18. Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R & Lange J, for the ATHENA Cohort Study Group. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17:1157-1165.
19. Autar RS, Mahanontharit A, Sangkote J, Chuenyam M, Ubolyam S, Kornkitsuwan P, Cooper D, Lange J, Phanupak P, Burger D & Ruxrungtham K. Therapeutic drug monitoring in Thailand: 2 years of experience (2002-2003). 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract TuPeB4636.
20. Ananworanich J, Cheunyam T, Teeratakulpisarn S, Boyd MA, Ruxrungtham K, Lange J, Cooper D & Phanuphak P. Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet 2004; 364:101-102.
21. Justesen US & Pedersen C. Diurnal variation of plasma protease inhibitor concentrations. AIDS 2002; 16:2487-2489.